论文信息 - Strengthening the Evidence: Similar Rates of Neural Tube Defects Among Deliveries Regardless of Maternal HIV Status and Dolutegravir Exposure in Hospital Birth Surveillance in Eswatini

Strengthening the Evidence: Similar Rates of Neural Tube Defects Among Deliveries Regardless of Maternal HIV Status and Dolutegravir Exposure in Hospital Birth Surveillance in Eswatini

Abstract Birth defect surveillance in Eswatini in 2020–2021 identified 0.80% defects (197/24 599 live and stillborn infants). Neural tube defect (NTD) prevalence was 0.08%, 0.08%, and 0.15% for 4902 women on dolutegravir preconception, 17 285 HIV-negative women, and 1320 women on efavirenz preconception, respectively, more definitively refuting the dolutegravir preconception NTD safety signal.

[1] Vijaya Kancherla. Neural tube defects: a review of global prevalence, causes, and primary prevention , 2023, Child's Nervous System.

[2] N. Garrett,et al. IMPLEMENTATION AND OUTCOMES OF DOLUTEGRAVIR-BASED FIRST-LINE ANTIRETROVIRAL THERAPY FOR PEOPLE WITH HIV IN SOUTH AFRICA: A RETROSPECTIVE COHORT STUDY , 2023, The lancet. HIV.

[3] A. Esber,et al. Transitioning women to first-line preferred TLD regimen is lagging in Sub-Saharan Africa. , 2022, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[4] S. Lockman,et al. Neural-Tube Defects and Antiretroviral Treatment Regimens in Botswana. , 2019, The New England journal of medicine.

[5] R. Shapiro,et al. Neural-Tube Defects with Dolutegravir Treatment from the Time of Conception. , 2018, The New England journal of medicine.

[6] D. H. Watts,et al. Teratogenicity risk of antiretroviral therapy in pregnancy. , 2007, Current HIV/AIDS reports.

[7] W. Stewart. Ministry , 1962 .